BHVN Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-03-18 | 2023 | Chief Scientific Officer | 489,850 | 385,757 | 0 | 0 | 7,420 | 2,584,248 |
| 2024-03-18 | 2023 | Chief Executive Officer | 840,000 | 1,102,500 | 0 | 0 | 16,059 | 6,819,189 |
| 2024-03-18 | 2023 | Senior Vice President, Clinical Operations | 470,487 | 370,509 | 0 | 0 | 17,656 | 2,559,873 |
| 2024-03-18 | 2023 | Chief Financial Officer | 551,250 | 482,388 | 0 | 0 | 20,778 | 2,755,637 |
| 2023-03-23 | 2022 | Chief Executive Officer | 200,000 | 1,050,000 | 0 | 0 | 705 | 5,971,479 |
| 2023-03-23 | 2022 | Chief Financial Officer | 131,250 | 413,438 | 0 | 0 | 1,015 | 2,036,473 |
| 2023-03-23 | 2022 | Chief Scientific Officer | 121,250 | 160,100 | 0 | 0 | 1,787 | 1,773,907 |
| 2022-03-11 | 2020 | Chief Commercial Officer of Migraine & Common Diseases | 483,000 | 422,625 | 0 | 0 | 26,190 | 931,815 |
| 2022-03-11 | 2021 | Chief Commercial Officer of Migraine & Common Diseases | 507,150 | 507,150 | 1,667,600 | 0 | 28,729 | 4,687,358 |
| 2022-03-11 | 2021 | Chief Financial Officer | 33,807 | 15,213 | 5,268,500 | 0 | 0 | 5,317,520 |
| 2022-03-11 | 2019 | Chief Executive Officer | 550,000 | 581,250 | 2,514,120 | 0 | 13,432 | 6,787,633 |
| 2022-03-11 | 2020 | Chief Executive Officer | 621,500 | 621,500 | 0 | 0 | 16,152 | 1,259,152 |
| 2022-03-11 | 2021 | Chief Executive Officer | 750,000 | 1,050,000 | 4,169,000 | 0 | 14,000 | 10,924,824 |
| 2022-03-11 | 2019 | Former Chief Financial Officer | 406,694 | 234,866 | 849,520 | 0 | 14,827 | 2,560,770 |
| 2022-03-11 | 2020 | Former Chief Financial Officer | 435,163 | 266,537 | 0 | 0 | 15,341 | 717,041 |
| 2022-03-11 | 2019 | Chief Medical Officer | 378,216 | 198,563 | 774,900 | 0 | 17,610 | 2,467,416 |
| 2022-03-11 | 2021 | Former Chief Financial Officer | 452,570 | 356,399 | 1,250,700 | 0 | 15,641 | 3,557,857 |
| 2022-03-11 | 2020 | Chief Medical Officer | 434,948 | 266,406 | 0 | 0 | 25,439 | 726,793 |
| 2022-03-11 | 2021 | Chief Medical Officer | 491,500 | 636,136 | 1,250,700 | 0 | 19,007 | 3,879,890 |
| 2022-03-11 | 2019 | Senior Vice President, Clinical Operations | 372,313 | 228,042 | 861,000 | 0 | 13,734 | 2,680,490 |
| 2022-03-11 | 2020 | Senior Vice President, Clinical Operations | 390,929 | 239,444 | 0 | 0 | 24,621 | 654,994 |
| 2022-03-11 | 2021 | Senior Vice President, Clinical Operations | 430,022 | 587,722 | 1,250,700 | 0 | 13,561 | 3,764,552 |
| 2022-03-11 | 2019 | Chief Commercial Officer of Migraine & Common Diseases | 345,000 | 936,000 | 688,800 | 0 | 14,478 | 5,605,745 |
| 2021-03-26 | 2019 | Senior Vice President, Clinical Operations | 372,313 | 228,042 | 861,000 | 0 | 13,734 | 2,680,490 |
| 2021-03-26 | 2020 | Chief Executive Officer | 621,500 | 621,500 | 0 | 0 | 16,152 | 1,259,152 |
| 2021-03-26 | 2019 | Chief Executive Officer | 550,000 | 581,250 | 2,514,120 | 0 | 13,432 | 6,787,633 |
| 2021-03-26 | 2018 | Chief Executive Officer | 500,000 | 437,500 | 0 | 0 | 12,500 | 5,294,638 |
| 2021-03-26 | 2020 | Chief Financial Officer | 435,163 | 266,537 | 0 | 0 | 15,341 | 717,041 |
| 2021-03-26 | 2019 | Chief Financial Officer | 406,694 | 234,866 | 849,520 | 0 | 14,827 | 2,560,770 |
| 2021-03-26 | 2018 | Chief Financial Officer | 380,800 | 233,240 | 0 | 0 | 14,028 | 2,257,307 |
| 2021-03-26 | 2020 | Chief Commercial Officer of Migraine & Common Diseases | 483,000 | 422,625 | 0 | 0 | 26,190 | 931,815 |
| 2021-03-26 | 2019 | Chief Commercial Officer of Migraine & Common Diseases | 345,000 | 936,000 | 688,800 | 0 | 14,478 | 5,605,745 |
| 2021-03-26 | 2020 | Senior Vice President, Clinical Operations | 390,929 | 239,444 | 0 | 0 | 24,621 | 654,994 |
| 2021-03-26 | 2018 | Senior Vice President, Clinical Operations | 327,250 | 198,297 | 0 | 0 | 15,192 | 1,952,746 |
| 2021-03-26 | 2020 | Chief Medical Officer | 434,948 | 266,406 | 0 | 0 | 25,439 | 726,793 |
| 2021-03-26 | 2019 | Chief Medical Officer | 378,216 | 198,563 | 774,900 | 0 | 17,610 | 2,467,416 |
| 2020-03-20 | 2019 | Chief Medical Officer | 378,216 | 198,563 | 774,900 | 0 | 17,610 | 2,467,416 |
| 2020-03-20 | 2018 | Senior Vice President, Clinical Operations | 327,250 | 198,297 | 0 | 0 | 15,192 | 1,952,746 |
| 2020-03-20 | 2019 | Senior Vice President, Clinical Operations | 372,313 | 228,042 | 861,000 | 0 | 13,734 | 2,680,490 |
| 2020-03-20 | 2019 | Chief Commercial Officer of Migraine & Common Diseases | 345,000 | 936,000 | 688,800 | 0 | 14,478 | 5,605,745 |
| 2020-03-20 | 2017 | Chief Financial Officer | 327,003 | 178,500 | 0 | 0 | 13,080 | 2,510,283 |
| 2020-03-20 | 2018 | Chief Financial Officer | 380,800 | 233,240 | 0 | 0 | 14,028 | 2,257,307 |
| 2020-03-20 | 2019 | Chief Financial Officer | 406,694 | 234,866 | 849,520 | 0 | 14,827 | 2,560,770 |
| 2020-03-20 | 2017 | Chief Executive Officer | 420,892 | 337,500 | 0 | 0 | 10,800 | 3,855,665 |
| 2020-03-20 | 2018 | Chief Executive Officer | 500,000 | 437,500 | 0 | 0 | 12,500 | 5,294,638 |
| 2020-03-20 | 2019 | Chief Executive Officer | 550,000 | 581,250 | 2,514,120 | 0 | 13,432 | 6,787,633 |
| 2019-04-11 | 2018 | SVP, Clinical Operations | 327,250 | 198,297 | 0 | 0 | 15,192 | 2,784,539 |
| 2019-04-11 | 2018 | Chief Commercial Officer | 309,000 | 162,225 | 0 | 0 | 18,849 | 1,525,674 |
| 2019-04-11 | 2017 | Chief Scientific Officer | 305,883 | 191,900 | 0 | 0 | 9,932 | 1,626,148 |
| 2019-04-11 | 2018 | Chief Scientific Officer | 334,960 | 205,163 | 0 | 0 | 8,932 | 2,792,855 |
| 2019-04-11 | 2016 | Chief Financial Officer | 222,592 | 137,025 | 0 | 0 | 4,908 | 482,823 |
| 2019-04-11 | 2017 | Chief Financial Officer | 327,003 | 178,500 | 0 | 0 | 13,080 | 2,510,283 |
| 2019-04-11 | 2018 | Chief Financial Officer | 380,800 | 233,240 | 0 | 0 | 14,028 | 3,217,068 |
| 2019-04-11 | 2016 | Chief Executive Officer | 350,000 | 245,000 | 0 | 0 | 0 | 784,428 |
| 2019-04-11 | 2017 | Chief Executive Officer | 420,892 | 337,500 | 0 | 0 | 10,800 | 3,855,665 |
| 2019-04-11 | 2018 | Chief Executive Officer | 500,000 | 437,500 | 0 | 0 | 12,500 | 7,854,000 |
| 2018-03-29 | 2017 | Vlad Coric, M.D. Chief Executive Officer | 420,892 | 337,500 | 0 | 0 | 10,800 | 3,855,665 |
| 2018-03-29 | 2017 | Charles Conway, Ph.D. | 305,883 | 191,900 | 0 | 0 | 9,932 | 1,626,148 |
| 2018-03-29 | 2016 | James Engelhart Chief Financial Officer | 222,592 | 137,025 | 0 | 0 | 4,908 | 482,823 |
| 2018-03-29 | 2017 | James Engelhart Chief Financial Officer | 327,003 | 178,500 | 0 | 0 | 13,080 | 2,510,283 |
| 2018-03-29 | 2016 | Vlad Coric, M.D. Chief Executive Officer | 350,000 | 245,000 | 0 | 0 | 0 | 784,428 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
